case
middl
east
respiratori
syndrom
coronaviru
merscov
continu
identifi
lack
effect
clinic
treatment
prevent
strategi
treatment
use
convalesc
plasma
monoclon
antibodi
mab
potenti
quick
rout
intervent
passiv
immunotherapi
via
either
convalesc
plasma
mab
proven
effect
infecti
agent
follow
infect
merscov
common
marmoset
treat
high
titer
hyperimmun
plasma
mab
h
post
inocul
treatment
reduc
sign
clinic
diseas
reduct
viral
load
respiratori
tract
found
hyperimmun
plasma
group
decreas
gross
patholog
found
mabtreat
group
histolog
differ
observ
treat
control
anim
hyperimmun
plasma
treatment
reduc
sever
diseas
common
marmoset
neither
treatment
result
full
protect
diseas
middl
east
respiratori
syndrom
coronaviru
merscov
first
detect
resid
saudi
arabia
sinc
result
case
case
fatal
rate
sever
epidem
potenti
merscov
highlight
import
develop
treatment
option
yet
specif
vaccin
antivir
treatment
merscov
avail
studi
publish
investig
effect
exist
antivir
treatment
treatment
thoroughli
assess
clinic
trial
yet
convalesc
plasma
identifi
world
health
organ
intern
sever
acut
respiratori
emerg
infect
consortium
isar
potenti
treatment
merscov
reduc
clinic
consequ
merscov
infect
recent
studi
protocol
develop
investig
feasibl
convalesc
plasma
treatment
mer
patient
arabi
et
al
vivo
administr
convalesc
sera
obtain
dromedari
camel
result
dosedepend
decreas
lung
viral
titer
diseas
sever
mous
model
sever
monoclon
antibodi
mab
develop
merscov
show
neutral
capac
vitro
jiang
et
al
tang
et
al
ying
et
al
efficaci
mab
assess
sever
merscov
mous
model
gener
show
reduct
viru
replic
corti
et
al
li
et
al
pascal
et
al
luke
et
al
studi
suggest
mab
potenti
merscov
treatment
mab
identifi
larg
phagedisplay
antibodi
librari
pan
recombin
merscov
spike
protein
receptor
bind
domain
inhibit
merscov
pseudoviru
infect
concentr
mgml
ying
et
al
shown
almost
complet
overlap
bind
site
mimic
critic
interact
merscov
spike
protein
modjarrad
et
al
therefor
specul
potenti
viral
escap
mutant
might
limit
requir
spike
protein
bind
ying
et
al
prophylact
treatment
result
significantli
reduc
viral
titer
rabbit
lung
tissu
houser
et
al
prophylact
therapeut
treatment
protect
mice
lethal
merscov
infect
agraw
et
al
assess
effect
treatment
marmosetderiv
hyperimmun
plasma
well
human
mab
diseas
outcom
recent
develop
marmoset
merscov
infect
model
recapitul
sever
respiratori
diseas
falzarano
et
al
approv
anim
experi
obtain
institut
anim
care
use
committe
rocki
mountain
laboratori
experi
perform
associ
assess
accredit
laboratori
anim
careapprov
facil
certifi
staff
follow
guidelin
basic
principl
unit
state
public
health
servic
polici
human
care
use
laboratori
anim
nih
guid
care
use
laboratori
anim
anim
welfar
act
unit
state
depart
agricultur
institut
biosafeti
committe
ibc
approv
work
infecti
merscov
strain
condit
sampl
inactiv
perform
accord
ibcapprov
standard
oper
procedur
remov
specimen
high
contain
hyperimmun
plasma
obtain
convalesc
common
marmoset
callithrix
jacchu
previou
experi
falzarano
et
al
inocul
tcid
merscov
via
intratrach
intranas
ocular
oral
rout
inocul
tcid
merscov
dpi
via
intratrach
rout
final
inocul
tcid
merscov
adjuv
titermax
gold
sigma
aldrich
dpi
via
intramuscular
rout
final
viru
neutral
vn
titer
method
chosen
sera
collect
initi
infect
contain
suffici
neutral
antibodi
vn
titer
control
plasma
obtain
uninfect
common
marmoset
intern
collect
vn
titer
common
marmoset
merscov
infect
model
use
merscov
infect
result
develop
sever
respiratori
diseas
observ
rhesu
macaqu
model
de
wit
et
al
munster
et
al
falzarano
et
al
common
marmoset
procur
usdaapprov
sourc
worldwid
primat
inc
anim
monitor
presenc
diseas
clinic
observ
serolog
presenc
diseas
worldwid
primat
inc
addit
anim
arriv
rocki
mountain
laboratori
place
quarantin
clinic
evalu
serum
chemistri
complet
blood
count
thorac
radiographi
confirm
absenc
previou
infect
three
differ
group
creat
hyperimmun
plasma
group
h
monoclon
antibodi
group
control
group
c
three
anim
randomli
assign
per
group
inocul
describ
previous
falzarano
et
al
briefli
inocul
merscov
strain
perform
intranas
ml
per
nare
oral
ml
intratrach
ml
ocular
ml
per
eye
dmem
contain
tcid
merscovml
total
dose
tcid
hyperimmun
plasma
monoclon
antibodi
group
consist
one
femal
two
male
common
marmoset
receiv
ml
hyperimmun
plasma
dilut
pb
mgml
intraven
iv
hpi
ml
hyperimmun
plasma
subcutan
sc
dpi
marmoset
two
three
anim
control
group
male
common
marmoset
receiv
ml
control
plasma
iv
hpi
ml
control
plasma
sc
dpi
marmoset
third
anim
receiv
ml
pb
diluent
mab
via
rout
marmoset
anim
observ
twice
daili
clinic
sign
diseas
use
score
system
describ
previous
falzarano
et
al
breath
score
normal
increas
minut
sever
increas
base
score
sheet
euthanasia
indic
clinic
score
clinic
exam
perform
dpi
anaesthet
anim
use
isofluran
ketamin
xray
taken
nasal
oral
fecal
urogenit
swab
collect
ml
dmem
uml
penicillin
mgml
streptomycin
blood
sampl
collect
dpi
examin
use
piccolo
xpress
chemistri
analyz
abaxi
blood
sampl
collect
dpi
obtain
treatment
administ
temperatur
monitor
temperatur
probe
bmd
inject
interscapularli
prior
start
experi
anim
euthan
dpi
fig
termin
blood
sampl
obtain
sampl
follow
tissu
collect
conjunctiva
nasal
mucosa
tonsil
trachea
four
lung
lobe
mediastin
lymph
node
liver
spleen
kidney
bladder
gross
patholog
surfac
area
lung
either
consolid
andor
hyperem
per
lung
lobe
document
percentag
area
affect
lesion
radiograph
imag
acquir
includ
ventrodors
right
later
left
later
thorac
imag
thorac
radiograph
obtain
use
mobil
digit
radiographi
unit
flat
panel
digit
detector
sound
technolog
trudr
soundeklin
carlsbad
ca
set
radiograph
grade
accord
publish
score
paradigm
brine
et
al
follow
normal
examin
mild
interstiti
pulmonari
infiltr
moder
interstiti
infiltr
perhap
partial
cardiac
border
effac
small
area
pulmonari
consolid
alveolar
pattern
air
bronchogram
pulmonari
consolid
primari
lung
patholog
seen
progress
grade
lung
patholog
grade
per
anim
done
independ
blind
two
veterinarian
provid
erasmu
medic
center
rotterdam
netherland
viru
propag
perform
cell
provid
bowen
laboratori
colorado
state
univers
dmem
supplement
fetal
calf
serum
mm
lglutamin
uml
penicillin
mgml
streptomycin
dmem
cell
maintain
dmem
supplement
fetal
calf
serum
mm
l
glutamin
uml
penicillin
mgml
streptomycin
marmoset
tissu
evalu
patholog
presenc
viral
antigen
tissu
fix
minimum
day
neutralbuff
formalin
subsequ
embed
paraffin
lung
perfus
formalin
process
histolog
review
lung
divid
right
upper
right
lower
left
upper
left
lower
lobe
four
section
sampl
hilu
midlob
peripheri
lobe
minimum
section
per
anim
method
use
nonhuman
primat
studi
rocki
mountain
laboratori
hereaft
tissu
section
stain
hematoxylin
eosin
detect
viral
antigen
immunohistochemistri
perform
use
inhous
produc
rabbit
polyclon
antiserum
grade
done
blind
boardcertifi
veterinari
pathologist
obtain
morphometr
data
immunohistochemistri
stain
stain
section
scan
aperio
scanscop
xt
aperio
technolog
inc
vista
ca
analyz
use
imagescop
posit
pixel
count
algorithm
version
mm
squar
evalu
magnif
default
paramet
posit
pixel
count
hue
width
detect
antigen
adequ
tissu
rna
analysi
collect
triplic
lung
tissu
obtain
hilar
midlob
region
lung
sampl
analyz
independ
duplic
tissu
mg
homogen
rlt
buffer
rna
extract
use
rneasi
method
qiagen
accord
manufactur
instruct
rna
extract
swab
use
qiaamp
viral
rna
kit
qiaxtractor
upe
merscov
detect
assay
use
detect
merscov
viral
rna
corman
et
al
ml
rna
test
rotorgenetm
probe
kit
qiagen
accord
instruct
manufactur
dilut
merscov
known
titer
run
parallel
dilut
vitro
transcrib
upe
merscov
rna
run
digit
droplet
pcr
biorad
quadrupl
determin
genom
copi
hereaft
dilut
run
rotorgenetm
quadrupl
last
dilut
give
ctvalu
replic
defin
limit
detect
lod
genom
copi
final
number
genom
copi
determin
merscov
dilut
known
titer
lod
calcul
tcid
equival
small
tissu
sampl
mg
ml
dmem
homogen
hereaft
merscov
titrat
quadrupl
cell
cell
inocul
tenfold
serial
dilut
tissu
homogen
incub
h
c
wash
twice
pb
score
cytopath
effect
day
later
tcid
adjust
tissu
weight
calcul
method
spearmankarb
twofold
serial
dilut
heatinactiv
min
c
marmoset
sera
prepar
dmem
tcid
merscov
viru
ad
incub
c
viru
ad
cell
dpi
cytopath
effect
score
viru
neutral
titer
express
reciproc
valu
highest
dilut
serum
still
inhibit
merscov
viru
replic
student
ttest
unpair
onetail
use
test
signific
p
valu
consid
signific
valu
report
mean
sd
final
vn
titer
hyperimmun
plasma
control
plasma
anim
inocul
tcid
merscov
strain
treat
iv
hpi
sc
hpi
two
differ
administr
rout
chosen
achiev
high
system
bioavail
iv
administr
immedi
result
high
circul
neutral
antibodi
titer
wherea
sc
administr
result
slower
system
distribut
antibodi
therefor
allow
longer
bioavail
wohlrab
anim
treat
hyperimmun
plasma
reach
neutral
titer
dpi
maintain
level
throughout
experi
anim
treat
reach
neutral
titer
dpi
decreas
dpi
contrast
serum
obtain
anim
treat
control
plasma
pb
contain
detect
level
neutral
antibodi
time
point
fig
upon
inocul
merscov
strain
anim
develop
clinic
diseas
clinic
score
control
group
anim
found
higher
clinic
score
treat
anim
post
inocul
fig
chang
bodi
temperatur
observ
anim
show
loss
appetit
decreas
activ
often
seen
combin
hunch
postur
chang
respiratori
rate
report
treat
anim
increas
respir
rate
breathsminut
observ
anim
progress
labor
breath
breath
minut
three
control
anim
one
treat
anim
accompani
open
mouth
breath
control
anim
radiograph
independ
blindli
grade
clinic
veterinarian
brine
et
al
view
normal
score
prior
inocul
day
within
control
group
three
anim
grade
dpi
sever
interstiti
infiltr
seen
earli
progress
pulmonari
consolid
within
caudal
middl
lung
lobe
dpi
score
hyperimmun
plasma
treatment
mab
treatment
group
averag
lower
grade
radiograph
comparison
control
group
dpi
one
hyperimmun
plasmatr
anim
character
grade
mild
interstiti
pulmonari
infiltr
left
caudal
lung
lobe
remain
two
hyperimmun
plasmatr
anim
either
moder
grade
sever
grade
radiograph
sign
one
mabtreat
anim
normal
radiograph
find
grade
throughout
durat
studi
wherea
two
anim
score
present
mild
radiograph
find
grade
fig
c
fig
blood
chemistri
valu
investig
use
piccolo
xpress
chemistri
analyz
day
post
inocul
overal
appar
differ
measur
clinic
chemistri
note
control
treat
group
valu
investig
paramet
bun
creatinin
alt
ast
alp
ggt
total
protein
glucos
calcium
found
within
normal
rang
marmoset
consist
pattern
trend
note
group
fig
gross
patholog
lung
score
boardcertifi
veterinari
pathologist
lung
lobe
dorsal
ventral
control
anim
median
percent
lesion
abnorm
patholog
find
observ
one
hyperimmun
plasmatr
anim
wherea
median
gross
patholog
lung
two
treat
anim
anim
treat
show
rel
littl
gross
patholog
median
differ
control
treat
anim
found
significantli
differ
use
unpair
onetail
student
ttest
hyperimmun
plasmatr
p
mabtreat
p
fig
measur
pulmonari
edema
inflamm
lung
bodi
weight
ratio
calcul
anim
signific
differ
observ
control
hyperimmun
plasmatr
group
howev
mabtreat
group
significantli
lower
lung
bodi
weight
ratio
control
group
p
fig
histolog
differ
observ
sever
natur
pneumonia
distribut
viral
antigen
control
treat
anim
marmoset
except
one
treat
marmoset
develop
lung
patholog
develop
multifoc
coalesc
moder
mark
subacut
bronchointerstiti
pneumonia
type
ii
pneumocyt
hyperplasia
adjac
alveolar
interstitium
thicken
congest
edema
fibrin
moder
number
macrophag
neutrophil
alveolar
space
contain
moder
mark
number
pulmonari
macrophag
neutrophil
immunohistochemistri
demonstr
small
number
pneumocyt
macrophag
posit
viral
antigen
cell
predominantli
associ
area
pneumonia
fig
differ
amount
viral
antigen
group
could
found
use
morphometr
analysi
dpi
nasal
oropharyng
urogenit
fecal
swab
collect
presenc
viral
rna
examin
via
quantit
revers
transcript
polymeras
chain
reaction
qrtpcr
viral
rna
presenc
often
detect
limit
except
two
one
nasal
swab
hyperimmun
plasmatr
anim
control
anim
respect
one
oral
fecal
swab
one
control
anim
dpi
instanc
urogenit
swab
neg
fig
upon
necropsi
anim
dpi
tissu
sampl
collect
presenc
viral
rna
tissu
analyz
use
qrtpcr
observ
previou
infect
marmoset
falzarano
et
al
highest
viral
load
found
lower
respiratori
tract
anim
fig
viral
load
lung
tissu
hyperimmun
plasmatr
compar
control
anim
found
significantli
lower
use
onetail
unpair
student
ttest
averag
tcid
equivalentgram
respect
pvalu
differ
found
signific
even
neg
valu
anim
exclud
analysi
averag
tcid
equivalentgram
pvalu
howev
treatment
marmoset
significantli
reduc
viral
load
lung
tissu
averag
tcid
equivalentgram
respect
pvalu
fig
viral
rna
found
nasal
turbin
trachea
conjunctiva
tonsil
mediastin
lymph
node
anim
pattern
relat
treatment
viral
rna
liver
spleen
kidney
bladder
limit
detect
fig
infecti
viru
could
found
tissu
sampl
current
specif
antivir
vaccin
approv
merscov
treatment
limit
inform
avail
efficaci
potenti
treatment
option
vivo
potenti
ventraldors
later
thorac
radiograph
well
gross
patholog
imag
marmoset
taken
dpi
shown
anim
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
treatment
merscov
would
use
neutral
antibodi
either
via
convalesc
plasma
monoclon
antibodi
sever
diseas
associ
delay
adapt
immun
respons
park
et
al
thu
antibodybas
therapi
might
benefici
administr
neutral
antibodi
earli
diseas
onset
patient
infect
respiratori
pathogen
sarscov
influenza
viru
report
benefici
mairjenkin
et
al
treatment
sarscovinfect
patient
convalesc
plasma
earli
diseas
progress
result
higher
likelihood
diseas
remiss
surviv
cheng
et
al
administ
convalesc
plasma
two
sarscovinfect
healthcar
worker
result
complet
recoveri
yeh
et
al
convalesc
plasma
treatment
patient
sever
influenza
viru
infect
result
reduc
mortal
respiratori
tract
viral
load
hung
et
al
metaanalysi
studi
treatment
spanish
influenza
convalesc
plasma
show
absolut
reduct
casefat
rate
luke
et
al
recent
studi
suggest
avail
donor
suffici
high
merscov
antibodi
titer
might
limit
test
sera
obtain
patient
healthcar
worker
household
contact
posit
elisa
arabi
et
al
furthermor
suggest
sever
diseas
link
serolog
respons
patient
develop
sever
diseas
upon
infect
merscov
higher
neutral
antibodi
level
detect
wherea
patient
mild
subclin
diseas
lower
potenti
shortliv
neutral
antibodi
level
detect
drosten
et
al
park
et
al
wellestablish
sever
diseas
link
preval
comorbid
badawi
ryoo
exist
might
contradict
collect
convalesc
serum
thu
pool
healthi
subject
suffici
neutral
antibodi
titer
convalesc
plasma
might
limit
final
hyperimmun
plasma
use
studi
high
neutral
antibodi
titer
wherea
best
human
convalesc
plasma
neutral
antibodi
titer
park
et
al
arabi
et
al
studi
use
differ
method
measur
neutral
antibodi
unclear
whether
convalesc
plasma
lower
neutral
titer
would
similar
effect
diseas
progress
lower
neutral
antibodi
titer
circul
like
reach
monoclon
antibodi
could
provid
altern
mab
treatment
healthi
volunt
inocul
influenza
viru
result
reduct
median
viral
load
nasal
swab
reduct
median
total
symptom
ramo
et
al
yet
studi
done
evalu
efficaci
convalesc
plasma
treatment
merscov
administr
camel
sera
mice
sensit
merscov
infect
result
decreas
viral
titer
lung
addit
repeat
studi
type
interferon
receptordefici
ifnar
mice
lose
weight
upon
inocul
merscov
decreas
weight
loss
well
less
sever
histolog
chang
lung
tissu
observ
far
one
document
merscov
case
receiv
convalesc
plasma
treatment
patient
still
hospit
day
ill
park
et
al
effect
mab
merscov
shown
vitro
jiang
et
al
tang
et
al
ying
et
al
prophylact
therapeut
administr
mab
merscov
mous
model
shown
decreas
viral
titer
load
found
lung
tissu
corti
et
al
li
et
al
pascal
et
al
luke
et
al
prophylact
treatment
via
iv
rout
result
significantli
reduc
viral
titer
fold
rabbit
lung
tissu
contrast
administr
dpi
via
rout
reduc
viral
rna
titer
lung
rabbit
houser
et
al
reduc
mortal
morbid
observ
merscov
mous
model
upon
intraperiton
prophylact
therapeut
treatment
therapeut
treatment
result
decreas
viral
titer
well
viral
rna
lung
tissu
agraw
et
al
argu
neither
rabbit
mous
model
high
predict
valu
potenti
mer
therapi
human
rabbit
remain
asymptomat
upon
inocul
merscov
infect
appear
promin
upper
respiratori
tract
suggest
diseas
progress
rabbit
differ
consider
observ
patient
requir
antivir
therapi
haagman
et
al
mous
model
valuabl
initi
valid
method
therapi
predict
valu
mous
model
therapeut
applic
human
rel
limit
oppos
nonhuman
primat
model
seok
et
al
studi
hyperimmun
plasma
treatment
marmoset
inocul
merscov
result
small
log
signific
reduct
respiratori
tract
viral
load
well
reduc
diseas
sever
observ
radiograph
compar
marmoset
treat
nonconvalesc
plasma
pb
howev
observ
differ
rel
minim
differ
histopatholog
observ
contrast
treatment
common
marmoset
result
signific
decreas
respiratori
tract
viral
load
compar
control
anim
howev
signific
reduct
diseas
sever
observ
pronounc
compar
diseaseassoci
sign
one
anim
treat
show
increas
respiratori
rate
breathsminut
anim
evid
infiltr
radiograph
show
decreas
level
gross
patholog
lowest
lung
bodi
weight
ratio
howev
chang
histolog
observ
compar
control
anim
qrtpcr
situ
stain
merscov
neg
lung
one
marmoset
treat
hyperimmun
plasma
although
merscov
viral
load
associ
patholog
detect
conjunctiva
anim
possibl
case
inocul
merscov
result
success
infect
respiratori
tract
remain
two
marmoset
treat
hyperimmun
plasma
found
viral
load
tcid
equival
per
gram
lung
tissu
marmoset
util
studi
outbr
signific
genet
factor
differ
immunolog
exclud
importantli
statist
test
perform
exclud
marmoset
viral
load
respiratori
tract
differ
tissu
marmoset
dpi
mean
valu
sd
calcul
statist
signific
calcul
use
onetail
unpair
student
ttest
pvalu
c
viral
load
extrarespiratori
tissu
marmoset
dpi
mean
valu
sd
calcul
red
hyperimmun
plasmatr
marmoset
blue
mabtreat
marmoset
green
control
marmoset
dot
line
limit
detect
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
viral
load
lobe
lower
respiratori
tract
control
hyperimmun
plasmatr
anim
still
signific
p
show
treatment
merscov
infect
anim
hyperimmun
plasma
result
lower
clinic
score
treatment
mab
reduc
occurr
sever
respiratori
symptom
hyperimmun
plasma
combin
less
gross
patholog
mab
might
therefor
better
therapi
goal
elev
symptom
associ
sever
mer
diseas
hyperimmun
plasma
reduc
viral
titer
reduct
viral
lung
load
result
less
sever
symptom
question
rais
import
chang
regardless
observ
differ
small
treat
anim
show
mildtomoder
respiratori
symptom
suggest
effect
treatment
limit
